Tugce Baser

Dr. Tugce Baser


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
TBTugce Baser
Tugce Baser
ARAhmet Sureyya Rifaioglu
Ahmet Sureyya Rifaioglu
MAMehmet Volkan Atalay
Mehmet Volkan Atalay
RCRengul Cetin-Atalay
Rengul Cetin-Atalay
Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer, with a high mortality rate due to the limited therapeutic options. Systemic drug treatments improve the patient’s life expectancy by only a few months. Furthermore, the development of novel small molecule chemotherapeutics is time-consuming and costly. Drug repurposing has been a successful strategy for identifying and utilizing new therapeutic options for diseases with limited treatment options. This study aims to identify candidate drug molecules for HCC treatment through repurposing existing compounds, leveraging the machine learning tool MDeePred. The Open Targets Platform, UniProt, ChEMBL, and Expasy databases were used to create a dataset for drug target interaction (DTI) predictions by MDeePred. Enrichment analyses of DTIs were conducted, leading to the selection of 6 out of 380 DTIs identified by MDeePred for further analyses. The physicochemical properties, lipophilicity, water solubility, drug-likeness, and medicinal chemistry properties of the candidate compounds and approved drugs for advanced stage HCC (lenvatinib, regorafenib, and sorafenib) were analyzed in detail. Drug candidates exhibited drug-like properties and demonstrated significant target docking properties. Our findings indicated the binding efficacy of the selected drug compounds to their designated targets associated with HCC. In conclusion, we identified small molecules that can be further exploited experimentally in HCC therapeutics. Our study also demonstrated the use of the MDeePred deep learning tool in in silico drug repurposing efforts for cancer therapeutics.

6 February 2026 in International Journal of Food Sciences and Nutrition
Verified
Journal Article
Closed access
TSTuğba Subaş
Tuğba Subaş
SCsumeyra cetinkaya
sumeyra cetinkaya
SSSeda Sirin
Seda Sirin
TBTugce Baser
Tugce Baser
ISIpek Suntar
Ipek Suntar
Obesity and its associated metabolic disorders, including type 2 diabetes mellitus, non-alcoholic fatty liver disease, and cardiovascular complications, represent a major global health burden. A key pathogenic mechanism linking these conditions is the overactivation of the NLRP3 inflammasome, which triggers caspase-1 activation and promotes proinflammatory cytokine release (e.g., IL-1β and IL-18), driving adipose tissue dysfunction, insulin resistance, and systemic inflammation. Emerging evidence highlights dietary polyphenols as natural modulators of NLRP3 activity attenuating inflammasome activation by regulating NF-κB signalling, reducing oxidative stress and restoring autophagy. Complementary in silico approaches (e.g., molecular docking, molecular dynamics simulations, network pharmacology) provide mechanistic insights into polyphenol-inflammasome interactions. This review summarises current evidence on the NLRP3's role in obesity-related disorders and discusses the therapeutic potential of dietary polyphenols, underscoring directions for translational and multidisciplinary research.